Introduction
Sleep problems are commonly seen in the general population, and insomnia is the most frequent complaint. When defined in accordance with standard diagnostic criteria, the prevalence of chronic insomnia ranges between 6 and 12% in the adult population (Pallesen et al., 2001; Ohayon, 2002) .
A wide range of sedative drugs is offered for insomnia in clinical practice. Hypnotics are most frequently prescribed, in particular nonbenzodiazepines such as Zolpidem, Zopiclone, and Eszopiclone, although benzodiazepines are still in use. Antihistamines, antidepressants, and neuroleptics with sedative effects are also prescribed (Morin and Wooten, 1996) . Short-term positive effects of hypnotics have been shown in meta-analyses (Nowell et al., 1997; Buscemi et al., 2007) , and for a long time less was known about the outcome of long-term treatment with hypnotics (Smith et al., 2002; Benca, 2005) . At the National Institutes of Health State of the Science Conference on Manifestation and Management of Chronic Insomnia it was therefore recommended to focus research on this issue (National Institutes of Health, 2005) . Indeed, data on effects of long-term treatment are now emerging, of which three placebo-controlled studies document positive long-term effects of drugs such as Zolpidem and Eszopiclone (Krystal et al., 2003; Walsh et al., 2007; Krystal et al., 2008) . Furthermore a recent review concluded that the risk/benefit ratio of the long-term use of sleep medications indicate that long-term use may be beneficial for a large proportion (Krystal, 2009 ). However, findings also indicate that long-term use is associated with negative consequences (e.g. Vermeeren, 2004; Glass et al., 2005) . In addition, it should be noted that none of the abovementioned long-term drug studies evaluated sleep with objective measures, such as polysomnography.
Prevalence rates of current and chronic use of sleep medications are commonly reported in the range between 6-10% (Quera-Salva et al., 1991; Ohayon, 1996; Pallesen et al., 2001; Souza et al., 2002) , whereas lifetime prevalence in terms of ever having taken sleep medications has been reported to be a little below 20% (Goodwin and Hasin, 2002; Souza et al., 2002) . It has recurrently been shown that the use of sleep medications is more common in women than in men and that usage increases with advancing age (Pallesen et al., 2001; Kassam and Patten, 2006; Kaneita et al., 2007) . Additional characteristics of users are less known, although some studies have indicated associations between usage and symptoms of depression and anxiety (Quera-Salva et al., 1991; Pallesen et al., 2001; Kaneita et al., 2007) , perceived impaired somatic health (Asplund, 2000) , reduced quality of life in women (Stein and Barrett-Connor, 2002) , and disagreeable sensations in the legs as well as interruption of sleep by snoring or dyspnea (Kaneita et al., 2007) .
Despite the common use of sleep medications, data regarding satisfaction with treatment are sparse. In terms of dependency on medications, most studies have investigated objective indicators such as withdrawal symptoms (Noble et al., 1998; Hajak, 1999; Holm and Goa, 2000) . A focus on subjective difficulty quitting as well as the relationship between usage and perceived control over sleep would therefore add to our knowledge of hypnotic use.
Research indicates that effective nonpharmacological treatments exist. For instance, comparative studies have shown that cognitive behavioural therapy has an advantage over sleep medications (Morin et al., 1999; Sivertsen et al., 2006) . Still, little is known of the extent to which patients are offered nonpharmacological treatment alternatives and what type of treatment they would prefer.
In some, there is a lack of knowledge about essential aspects of the use of sleep medications, such as satisfaction with treatment effect and difficulty in quitting the drugs. In addition, more information is needed concerning to what extent nonpharmacological treatment options are being offered as alternatives to hypnotics. In order to understand factors related to the use of sleep medications, it is important to identify predictors for different patterns of use. Against this background we conducted a survey in a representative sample of the Norwegian adult population addressing the following questions: (i) What characterizes sleep medication users in terms of demographic variables, perceived control over sleep, symptoms of anxiety and depression, treatment satisfaction, and difficulty in quitting sleep medications? (ii) How often is nonpharmacological treatment offered for sleep problems, and what type of treatment do people prefer? (iii) What is the prevalence of lifetime, current, and chronic use of sleep medications? (iv) Which factors predict sleep medication use? (v) Which factors predict treatment satisfaction, difficulty in quitting sleep medications, and treatment preference of sleep medication versus nonpharmacological treatment alternatives?
Methods

Participants
In all, 1353 women (51.2%) and 1292 men participated in the study. The mean unweighted age of the respondents was 48.1 years (SD=15.3; range=18-79), and the distribution in the age categories 18-34 years, 35-49 years, 50-64 years, and 65-79 years was 22.0, 30.7, 30.9, and 16.4%, respectively . Of the total sample, 14.6% had no education subsequent to 9 years of mandatory schooling or less. The frequency distributions of this group increased with age and amounted to 3.8, 7.0, 19, and 36.0%, in the abovementioned age categories, respectively.
Procedure
Statistics Norway was responsible for sampling and distribution of the survey. The sample was randomly drawn from the Norwegian National Registry in September 2006 and included 5000 adults who ranged in age from 18-79 years. The survey was administered as a postal questionnaire in October 2006, and the respondents who did not reply within 3 to 4 weeks received a reminder. Until two reminders were sent a total of 2645 participants responded, yielding a response rate of 52.9%.
Instruments
The majority of questions in the survey were adapted from validated assessment tools including the Bergen Insomnia Scale (Pallesen et al., 2008) , the Global Sleep Assessment Questionnaire (Roth et al., 2002) , the Structured Clinical Interview for DSM (First et al., 1995) , the World Health Organization's quality of life assessment questionnaire (Harper and Power, 1998) , and the Severity of Dependence Scale (Gossop et al., 1995) . The survey addressed socioeconomic status, symptoms of sleep disorders, perceived control over sleep, symptoms of anxiety and depression, satisfaction with health, and quality of life (see Appendix). Information about age and sex was available from Statistics Norway.
In order to make the results from the statistical analyses easier to follow, most variables were recoded. Age was coded into the four following groups: (i) 18-34 years, (ii) 35-49 years, (iii) 50-64 years, and (iv) 65-79 years. Socioeconomic status was based on educational level and was defined as either low (i.e. education r 9 years of mandatory schooling) or high (i.e. education > 9 years of mandatory schooling). The depression and anxiety variables as well as the sleep disorder variables were coded according to reported symptom frequency as either 'nonfrequent symptoms' (i.e. never and sometimes) or 'frequent symptoms' (i.e. most of the time and all the time). Furthermore, satisfaction with health was categorized as 'not satisfied' (i.e. not at all satisfied, dissatisfied, and neither satisfied nor dissatisfied) or 'satisfied' (i.e. satisfied and very satisfied), and quality of life was coded as 'poor' (i.e. very poor, poor, and neither poor nor good) or good (i.e. good and very good). Perceived control over sleep was dichotomized into 'low control' (0-4) or 'high control' (5-10). Of the dependent variables, satisfaction with the use of sleep medication was coded as either 'not satisfied' (i.e. not at all satisfied, dissatisfied, and neither satisfied nor dissatisfied) or 'satisfied' (i.e. satisfied and very satisfied). Difficulty in quitting current use of sleep medications was coded as either 'not difficult' (i.e. not difficult) or 'difficult' (i.e. quite difficult, very difficult, and impossible).
Insomnia was operationalized in accordance with the essential diagnostic features of the disorder, hereunder difficulties initiating and maintaining sleep as well as daytime impairment (World Health Organization, 1992; American Psychiatric Association, 2000; American Academy of Sleep Medicine, 2005) .
Lifetime prevalence was defined as having used medication prescribed for sleep problems at least on one occasion in life, whereas current prevalence was defined as having used such medication at least once during the last month. Chronic use was defined as having used prescribed medication at least 3 days or more per week for more than 6 months at some time in life.
Statistics
All statistical analyses were conducted with SPSS version 14 (SPSS Inc, Chicago, Illinois, USA). To correct for any bias in the study sample, all prevalence figures and inferential statistical analyses (see Tables 1-3) were weighted according to the distribution of age and sex in the Norwegian population. In order to investigate if the categorical variables were significantly related to lifetime, current, or chronic use of sleep medication, Pearson's chi-square tests were run. Weighted logistic regression was used to identify significant predictors for the use of sleep medication, satisfaction with treatment effect, difficulty in quitting sleep medications, and preference of nonpharmacological or pharmacological treatment, and both crude and adjusted analyses were conducted. In the crude analyses each predictor was entered separately, whereas all the predictors were entered in the adjusted analyses. Odds ratios and 95% confidence intervals were calculated, and the odds ratios were considered statistically significant when the confidence interval did not include the value 1.00. The number of observations varied across the analyses because of missing data, which were handled by excluding cases. Lifetime prevalence was defined as having used medication prescribed for sleep problems at least on one occasion in life (n = 491). b Current prevalence was defined as having used sleep medication at least once during the last month (n = 206). c Chronic use was defined as having used sleep medication at least 3 days or more per week for more than 6 months at some point in life (n = 110 Symptoms of sleep apnea. *Significant at the 0.05 level (two-tailed); **Significant at the 0.001 level (two-tailed).
Ethics
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Results
Respondent characteristics and prevalence of sleep medication use
The respondents reported an average sleep time of 6 h and 45 min per night and that their mean sleep need was 7 h and 25 min, thus the mean reported sleep debt was 40 min. In all, 40.5% of the respondents had experienced a period with sleep problems during their lifetime lasting for 1 month or longer. Furthermore, 13.1% fulfilled the criteria for insomnia during the last month, and 2.4% reported to have experienced repeated rhythmic leg jerks or twitches during sleep, 4.6% restless or crawling feelings in the legs, and 2.2% breathing pauses either usually or always during sleep in the past 4 weeks. With regard to anxiety and depression, 4.0% reported frequent anxiety symptoms and 4.0% frequent depression symptoms during the last month. In addition 4.4% reported that they were not satisfied with their health and 12.1% rated their quality of life as poor.
The prevalence of lifetime, current and chronic use of prescribed sleep medications were 18.8, 7.9, and 4.2%, respectively. The rates were significantly higher in older participants, women, and those with a maximum of 9 years of education (see Table 1 ). The most commonly used sleep medications during the last month were the so-called Z-drugs (e.g. zopiclone and zolpidem), which had been taken at least once by 62.7% of the current users. Furthermore, benzodiazepines had been taken by 4.4%, anxiolytics by 17.0%, antidepressives by 14.6%, Lifetime prevalence was defined as having used medication prescribed for sleep problems at least on one occasion in life.
b Current prevalence was defined as having used sleep medication at least once during the last month. c Chronic use was defined as having used sleep medication at least 3 days or more per week for more than 6 months at some point in life (n = 110). antihistamines by 10.3%, and antipsychotics by 9.2% (see appendix for a detailed list of the generic names). The current users took the sleep medications on average 4.4 (SD=2.5) nights per week.
Lifetime, current, and chronic use of prescribed sleep medication were significantly higher in respondents who were not satisfied with their health, had a poor quality of life, experienced low control over sleep, and who had frequent symptoms of anxiety or depression. Lifetime use was in addition significantly higher in respondents who reported frequent symptoms of restless legs, and current use was higher in respondents who reported frequent symptoms of restless legs and sleep apnea (breathing pauses; see Table 1 ). Among the current users, 86.9% reported satisfaction with the effect of sleep medications whereas 59.9% stated that it would be difficult to stop taking them. Of those who had ever used sleep medications, 80.3% reported that they would prefer nonpharmacological over pharmacological treatment for their problems given that the treatments were equally effective. Only a minority comprising 9.6% of this group had actually been offered other than pharmacological treatment.
Predictors of sleep medication use
Female sex and older age appeared as consistent and significant predictors for lifetime, current, and chronic use. Low socioeconomic status was positively associated with use in all the crude analyses. However, the associations did not remain significant in the adjusted analysis neither for lifetime nor for chronic use, and in contrast a negative association appeared for current use (see Table 2 ).
Among the sleep disorder symptoms, repeated rhythmic leg movements during sleep was a significant predictor for both lifetime and current use of sleep medication in the adjusted analyses, whereas breathing pauses during sleep predicted only current use. Furthermore, restless or 'crawling' feelings in the legs predicted lifetime and current use, but only in the crude analyses. None of the sleep disorder symptoms predicted chronic use of sleep medications (see Table 2 ).
Low perceived control over sleep significantly predicted lifetime, current, and chronic use of sleep medications. The same was true for frequent depressive symptoms, whereas frequent anxiety symptoms remained significant in the adjusted analyses only for current use. Nonsatisfaction with health appeared as a significant predictor of sleep medication use in both the crude and adjusted analyses, whereas quality of life only appeared as significant in the crude analyses (see Table 2 ).
Predictors of difficulty in quitting sleep medications, treatment satisfaction, and preference of treatment Age (50 years and above) predicted subjectively reported difficulty in quitting sleep medications as well as satisfaction with the treatment effect. Female sex also predicted satisfaction, whereas poor quality of life predicted nonsatisfaction. In addition, satisfaction was negatively related to low perceived control over sleep, but only in the crude analysis. Difficulty in quitting sleep medications was in contrast positively related to low perceived control over sleep, also in the adjusted analyses (see Table 3 ).
Both age (65 years and above) and nonsatisfaction with health predicted a preference for pharmacological over nonpharmacological treatment for sleep problems. This was also true for the presence of breathing pauses during sleep, but only in the crude analysis. In contrast, high socioeconomic status predicted a preference for nonpharmacological treatment, although the association did not remain significant in the adjusted analysis (see Table 3 ).
Discussion
Respondent characteristics and prevalence of sleep medication use
In accordance with earlier research, the respondents on average reported to sleep less than their perceived sleep need (Pallesen et al., 2001; Ursin et al., 2005; Anderson and Horne, 2008) . The prevalence rate for insomnia (13.1%) was representative of what has been reported in earlier epidemiological studies (Hohagen et al., 1994; Pallesen et al., 2001 ).
Approximately one in five had used sleep medication at least once during their life, whereas about one in 25 had used it chronically at some point in life. Considering the wide operationalization of lifetime prevalence that was used in our study, this finding may be understood as an expression of how familiar the general population is with the drugs. A comparison of lifetime prevalence with the more carefully defined chronic prevalence may represent an estimate of the difference between acute and chronic use. Acute use may reflect more occasional and even coincidental use, whereas chronic use is likely to be related to persisting sleep problems. Since the prevalence of current use of sleep medication was almost 8%, and since the prevalence of chronic use was about 4%, it seems reasonable to conclude that at least half of those who took sleep medication within the last month used it on a nonchronic basis. Finally, the use was associated with poor mental health and poor sleep, and it was more common in women and in older age.
Predictors of the use of sleep medications
Age and sex appeared as significant predictors for lifetime, current, and chronic use of sleep medications. These findings are in line with studies showing a female preponderance in insomnia (Ancoli-Israel and Roth, 1999; Husby and Lingjaerde, 1990; Pallesen et al., 2001) , and consequently that high age in itself increases the likelihood of having used sleep medication at some point in life. However, the fact that age also predicted current use may reflect the common finding that sleep problems increase with advancing age (Husby and Lingjaerde, 1990; Pallesen et al., 2001 ). It should not be ruled out, however, that the prescription of sleep medication may be practiced more leniently as patients get older or alternatively that patients are more willing to use pills for their sleep problems as they age, or a combination of these factors. Higher socioeconomic status predicted a lower lifetime, current, and chronic use in the crude analyses, but higher current use in the adjusted analyses. A possible explanation of the directional change of the relationship may be that age mediated the effects in the crude analyses as the frequency of participants with no education subsequent to mandatory schooling increased with age. Contrary to what might be expected then, belonging to the high socioeconomic status group increased the likelihood of using sleep medications currently.
With regard to symptoms of sleep disorders, leg movements were negatively associated with both lifetime and current use, whereas the occurrence of breathing pauses during sleep was positively associated with current use of sleep medications. The finding regarding breathing pauses is worrisome as hypnotics are counter-indicated for sleep apnea (Guilleminault, 1990; Lu et al., 2005) . Overall, the data suggest that the presence of sleep disorder symptoms plays a more prominent role in explaining current use than lifetime or chronic use of sleep medications as no relationship was observed between the sleep disorder variables and chronic use of sleep medications.
Current use of sleep medications was predicted by low satisfaction with health and frequent symptoms of depression and anxiety both in the crude and the adjusted analyses, thus underscoring the commonly observed association between sleep problems and emotional and psychological distress (Ford and Kamerow, 1989; Jansson and Linton, 2006; Johnson et al., 2006) . Quality of life predicted current use only in the crude analysis, implying that symptoms of depression and anxiety, as well as health perception, probably act as mediators of quality of life. A feasible interpretation of these findings is that people who do not suffer from poor health tend to be satisfied with their lives and have good sleep, thus they do not need to take sleep medications.
Overall, there were few differences in terms of which of the predictor variables that were associated with the various prevalence rates. One exception to this was that symptoms of sleep disorders for the most part predicted current use and not so much lifetime or chronic use of sleep medications. Older age and the experience of having low control over sleep were the two most prominent predictors of the use of sleep medications. From research in other clinical domains it is known that a perceived lack of control is associated with psychological problems (Tan et al., 2002; McLaren and Crowe, 2003; Wardle et al., 2004; Hoedemaekers et al., 2007) . Thus, it may be assumed that a potential weakness with pharmacological treatment for sleep problems is that medications fail to increase perceived control over sleep, possibly because the users attribute improvement to the pills they are taking (Storms and Nisbett, 1970; Hauri, 1997) .
Predictors of treatment satisfaction, difficulty in quitting sleep medications, and treatment preference
In general the satisfaction with taking sleep medications was high, indicating that most users experienced at least some relief from their sleep problems. Poor quality of life predicted nonsatisfaction with sleep medications, which supports the idea that poor sleep and reduced quality of life are related (Schubert et al., 2002; Dixon et al., 2006) .
A majority of the current users reported difficulty with quitting the drugs. This may represent dependence on the drugs or reflect an actual persistence of the sleep problem. Age predicted satisfaction with drug treatment as well as difficulty in quitting the sleep medications, which may indicate a tendency of older people to be less resistant to taking drugs. This interpretation is reinforced by the finding that nonsatisfaction with health and being in the oldest age group predicted a preference for pharmacological over nonpharmacological treatment for their sleep problems, thus implying that the pharmacological treatment model may be more accepted in older age than among younger people. These findings also appear logically consistent, as it can be assumed to be more difficult to stop taking a drug that gives relief than a drug that does not have the intended therapeutic effect.
Furthermore, low perceived control over sleep appeared as another significant predictor of difficulty in quitting sleep medications, supporting the idea that the degree of control that one feels over sleep may play a significant role in the pattern of sleep medication use. Consequently, we may assume that increased perceived control may work to counter subjective feelings of dependency, and thus to overcome negative patterns of sleep medication use. This assumption remains to be investigated further.
Nonpharmacological treatment
Sleep medications were by far the most commonly offered treatment for sleep problems in the current population study, and only a minority of those who had used sleep medication had ever been offered nonpharmacological treatment. This trend corresponds with findings from another recent Norwegian population study showing that sleep medications frequently are being prescribed for new users (Hausken et al., 2009) . Still, the current study showed that as many as four out of five respondents would actually prefer nonpharmacological treatment than sleep medications for their sleep problems given that the treatments would be equally effective. This finding is in line with the results from earlier study (Vincent and Lionberg, 2001) . Taken together, the findings implicate that a stronger emphasis should be put on integration of nonpharmacological treatment in the health care services.
Limitations
One limitation of this study is that the response rate was lower than ideal for an epidemiologic study. However, this represents an inherent problem with all postal surveys (Edwards et al., 2007) , and the achieved rate is comparable to what has been reported in similar epidemiological studies (Ancoli-Israel and Roth, 1999; Pallesen et al., 2001) . Furthermore, to overcome potential problems with unequal response rates across sex and age groups, the sample was weighted according to the population distribution of these variables.
Another limitation, which derives from the cross-sectional nature of the study, is that any relationship between the variables can be characterized only as associations and not as causal relationships. This means, for example, that it is not possible to infer the direction of the relationship between depression and the use of sleep medications from this current study.
Another problem is that the questions about sleep medication use were retrospective in nature, and thus that the answers to them may have been be blurred by faulty memory. An implication of this is, for instance, that the concept of lifetime prevalence represents a subjective estimate. In addition, the data regarding symptoms of sleep disorders should be interpreted with caution as it is generally accepted that reliable identification of many sleep disorders requires the use of polysomnography and because hypnotics might impair the awareness and memory of sleep events.
Finally, it should be taken into account that the data exclusively concerned prescribed drugs, omitting overthe-counter drugs. Similarly, specific questions pertaining to actually receiving nonpharmacological treatment were not included; thus, we were precluded from comparing nonpharmacological treatment and sleep medication in terms of satisfaction, etc.
Summary and conclusions
Approximately 8% used sleep medications currently, and it can be assumed that at least half of the current users took the medication on a nonchronic basis. Use was more common in women and older people, as well as in people with poor sleep and poor mental health. Age and low perceived control over sleep were the strongest predictors of use and difficulty in quitting sleep medications, indicating that the degree of perceived control over sleep may play a significant role in explaining the drug pattern use.
The majority of respondents would prefer nonpharmacological treatment for their sleep problems, but only a minority had been offered alternatives to medications. A more extensive integration of nonpharmacological approaches to sleep problems should be aimed for by the health care services. Clinical guidelines for insomnia care should include the application of careful assessment procedures and offering patients nonpharmacological treatment alternatives where these are warranted.
